Raymond James Trust N.A. Sells 2,252 Shares of Haleon plc (NYSE:HLN)

Raymond James Trust N.A. reduced its stake in Haleon plc (NYSE:HLN) by 4.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 49,168 shares of the company’s stock after selling 2,252 shares during the period. Raymond James Trust N.A.’s holdings in Haleon were worth $520,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Fortitude Family Office LLC acquired a new position in Haleon in the 3rd quarter valued at $28,000. Cultivar Capital Inc. bought a new position in shares of Haleon in the second quarter worth $40,000. Prospera Private Wealth LLC acquired a new position in Haleon in the third quarter valued at about $57,000. Hexagon Capital Partners LLC lifted its position in Haleon by 66.6% during the second quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock worth $55,000 after purchasing an additional 2,677 shares during the period. Finally, BOKF NA grew its stake in Haleon by 68.8% during the second quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after buying an additional 2,842 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on HLN shares. Morgan Stanley boosted their target price on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th. The Goldman Sachs Group cut Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Berenberg Bank initiated coverage on Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating on the stock. Finally, UBS Group raised Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $10.95.

Haleon Price Performance

Shares of NYSE:HLN opened at $9.58 on Tuesday. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company has a market cap of $43.37 billion, a price-to-earnings ratio of 28.18, a PEG ratio of 2.91 and a beta of 0.30. The firm has a 50 day simple moving average of $10.01 and a 200 day simple moving average of $9.39.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.